Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial

Thumbnail Image

Files

Journal Article.pdf (1.57 MB)

Date

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

WOS

URI

https://hdl.handle.net/10539/44179

Collections

Academic Wits Research Outputs (All submissions)

Endorsement

Review

Supplemented By

Referenced By